Innate Pharma S.A. (NASDAQ:IPHA) Sees Significant Decline in Short Interest

Innate Pharma S.A. (NASDAQ:IPHA) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 101,000 shares, a decrease of 88.9% from the December 31st total of 909,800 shares. Based on an average daily volume of 467,300 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $11.50 price target on shares of Innate Pharma in a research note on Friday, January 17th.

Innate Pharma Price Performance

NASDAQ:IPHA remained flat at $1.76 during trading hours on Wednesday. The company’s stock had a trading volume of 21,696 shares, compared to its average volume of 53,840. Innate Pharma has a 52-week low of $1.29 and a 52-week high of $3.51. The company’s fifty day simple moving average is $1.81 and its 200 day simple moving average is $1.99.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.